17
Participants
Start Date
November 17, 2017
Primary Completion Date
May 14, 2018
Study Completion Date
May 14, 2018
Continuous infusion high-dose MCI-186
intravenous injection
Continuous infusion low-dose MCI-186
intravenous injection
Continuous infusion placebo
intravenous injection
Approved dosing regimen MCI-186
intravenous injection
Approved dosing regimen placebo
intravenous injection
Investigational site 13, Aichi
Investigational site 39, Aomori
Investigational site 19, Chiba
Investigational site 28, Chiba
Investigational site 33, Ehime
Investigational site 10, Fukui
Investigational site 05, Fukuoka
Investigational site 09, Fukuoka
Investigational site 11, Fukuoka
Investigational site 12, Fukuoka
Investigational site 18, Fukuoka
Investigational site 21, Fukuoka
Investigational site 32, Fukuoka
Investigational site 37, Fukuoka
Investigational site 07, Fukushima
Investigational site 08, Fukushima
Investigational site 15, Gifu
Investigational site 23, Gifu
Investigational site 02, Gunma
Investigational site 01, Hokkaido
Investigational site 22, Hokkaido
Investigational site 06, Hyōgo
Investigational site 30, Hyōgo
Investigational site 42, Hyōgo
Investigational site 43, Ishikawa
Investigational site 40, Kanagawa
Investigational site 24, Kochi
Investigational site 35, Miyagi
Investigational site 16, Nagano
Investigational site 20, Nagano
Investigational site 27, Numakunai
Investigational site 44, Okayama
Investigational site 41, Okinawa
Investigational site 03, Osaka
Investigational site 25, Osaka
Investigational site 38, Saga
Investigational site 31, Saitama
Investigational site 14, Shimane
Investigational site 29, Tochigi
Investigational site 36, Tochigi
Investigational site 17, Tokyo
Investigational site 45, Tokyo
Investigational site 34, Yamagata
Investigational site 04, Yamaguchi
Investigational site 26, Yamaguchi
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
INDUSTRY